• Aucun résultat trouvé

Mantle Cell Lymphoma (MCL)

Results from the Belgian mantle cell lymphoma registry

Results from the Belgian mantle cell lymphoma registry

... Introduction: Mantle cell lymphoma is a B-cell non-Hodgkin’s lymphoma characterized by a t(11;14), resulting in overexpression of cyclin ...of Mantle cell lymphoma ...

8

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

... 7 Abstract The combination of carmustine, etoposide, cytarabine, and melphalan (BEAM) as conditioning regimen prior to autologous stem-cell transplantation (ASCT) remains the standard of care for patients with ...

49

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.: MRD after immunochemotherapy in mantle-cell lymphoma

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.: MRD after immunochemotherapy in mantle-cell lymphoma

... Introduction Mantle cell lymphoma (MCL) is characterized by a mostly advanced stage of disease at diagnosis and an aggressive clinical course with a short median overall survival (OS) of 3-4 years ...

32

Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma

Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma

... inhibitor (PI) bortezomib (BTZ), also known as Velcade, was, in 2003 and 2006, the first Food and Drug Administration (FDA)-approved PI for the treatment of two haematological malignancies: multiple myeloma (MM) and ...

32

Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project

Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project

... Mantle cell lymphoma (MCL) is an incurable aggressive non-Hodgkin lymphoma (NHL), which accounts for approximately 5% of all ...various lymphoma entities, 3 but its utility in MCL ...

20

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma

... MCL is usually diagnosed as a late-stage disease that has typically spread to the gastrointestinal tract and bone mar- row [8]. MCL is often associated with temporary response to therapy, varying from months to decades, ...

9

Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.

Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.

... Background Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin’s lymphoma (NHL), representing about 6% of NHL ...and cell cycle deregulation ...

5

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.

... MCL is usually diagnosed as a late-stage disease that has typically spread to the gastrointestinal tract and bone mar- row [8]. MCL is often associated with temporary response to therapy, varying from months to decades, ...

9

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

... of mantle cell lymphoma (MCL) and its short response to current treatment highlight a great need for better rational ...MCL cell lines tested (n = 8), only three were sensitive (LD 50 < 200 ...

11

Management of Drug Resistance in Mantle Cell Lymphoma

Management of Drug Resistance in Mantle Cell Lymphoma

... Abstract: Mantle cell lymphoma (MCL) is a rare but aggressive B-cell hemopathy characterized by the translocation t(11;14)(q13;q32) that leads to the overexpression of the cell cycle ...

26

Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.

Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.

... untreated mantle cell lymphoma patients (according to the WHO classifica- tion 1 ) were enrolled in the two consecutive phase II trials by the French GOELAMS group described ...

9

en
                                                                    fr

en fr Physiopathology of mantle cell lymphoma from mechanistic to preclinical models Physiopathologie du lymphome à cellules du manteau : de la mécanistique aux modèles précliniques

... THP1 cell line, selected for acquired resistance to bortezomib, the PSMB5 gene coding for PSMB5, the β5 subunit, is mu- tated and the corresponding protein overexpressed ...Cancer Cell Line Ecyclopedia) ...

229

BMP7 Expression Correlates with Secondary Drug Resistance in Mantle Cell Lymphoma

BMP7 Expression Correlates with Secondary Drug Resistance in Mantle Cell Lymphoma

... in lymphoma cells and in normal germinal center B-cells ...B-cell lymphoma cells can escape BMP-induced inhibition of cell growth suggesting an autocrine growth regulation and that malignant ...

10

Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma.

Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma.

... Inhibition of LYN activity is associated with an increase of apoptosis in MCL cells The BCR signal is initially transmitted by LYN kinase leading to activation of various signaling pathways including JNK. We therefore ...

15

Treatment of mantle cell lymphomas: recommendations of the Belgian Hematological Society

Treatment of mantle cell lymphomas: recommendations of the Belgian Hematological Society

... The Mantle Cell Lymphoma International Prognostic Index (MIPI) is a recently established clinical and biological score for pre-treatment risk assessment in patients with advanced-stage ...

8

Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.

Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.

... L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignemen[r] ...

2

Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma

Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma

... cells lymphomas. Indeed, an increased expression of both CD86 and CD80 in response to TLR9 stimulation was shown in chronic lymphocytic leukemia, but not in response to TLR7 stimulations [21]. Follicular lymphoma ...

11

The therapeutic effectiveness of 177Lu-lilotomab in B-cell non- Hodgkin lymphoma involves modulation of G2/M cell cycle arrest

The therapeutic effectiveness of 177Lu-lilotomab in B-cell non- Hodgkin lymphoma involves modulation of G2/M cell cycle arrest

... These results are of a particular relevance because inhi- bitors of proteins required for cell cycle progression (e.g., CHK1/2, CDK4/CDK6, CDK1, and WEE-1) have gained interest for the treatment of solid and ...

15

Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets.: Molecular Signature of Hepatosplenic T-cell Lymphoma

Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets.: Molecular Signature of Hepatosplenic T-cell Lymphoma

... lines 42 . Although HSTL is reported as a fatal disease, recent reports have described long survivors after cytarabine-based chemotherapy 4 . The present findings might provide a rationale for the use of cytarabine ...

41

Description of Two Cases of Anaplastic Large Cell Lymphoma Associated with a Breast Implant

Description of Two Cases of Anaplastic Large Cell Lymphoma Associated with a Breast Implant

... large cell lymphoma (BIA-ALCL) is a recently recognized provisional entity in the 2017 revision of the World Health Organization classification of lymphoid ...

7

Show all 3879 documents...

Sujets connexes